{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:27:58Z","timestamp":1792672078949,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15367-0","type":"journal-article","created":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T15:51:06Z","timestamp":1755445866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel solid phase synthesis of an estradiol derivative and preclinical evaluation for targeting estrogen-receptor positive breast cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Subhani M.","family":"Okarvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,17]]},"reference":[{"key":"15367_CR1","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cancers12051312","volume":"12","author":"J Lau","year":"2020","unstructured":"Lau, J. et al. Insight into the development of PET radiopharmaceuticals for oncology. Cancers 12, 1312 (2020).","journal-title":"Cancers"},{"key":"15367_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7150\/thno.4024","volume":"2","author":"M Fani","year":"2012","unstructured":"Fani, M., Maecke, H. M. & Okarvi, S. M. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2, 481\u2013501 (2012).","journal-title":"Theranostics"},{"key":"15367_CR3","unstructured":"Gradishar, W. J. et al. NCCN Clinical practice guidelines in oncology. Breast cancer, version 5 2020.. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. (2020)."},{"key":"15367_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J. Clin. Oncol. 38, 1346\u20131366 (2020).","journal-title":"J. Clin. Oncol."},{"key":"15367_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2009.09.009","volume":"46","author":"RW Blamey","year":"2010","unstructured":"Blamey, R. W. et al. ONCOPOOL \u2013 A European database for 16,944 cases of breast cancer. Eur. J. Cancer. 46, 56\u201371 (2010).","journal-title":"Eur. J. Cancer"},{"key":"15367_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdx651","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso, F. et al. Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG. International male breast cancer program. Ann. Oncol. 29, 405\u2013417 (2018).","journal-title":"Ann. Oncol."},{"key":"15367_CR7","unstructured":"Thompson, E. B. et al. Steroid Receptors and the Management of Cancer. Vol. 1, 1\u2013248 (CRC Press, 1979)."},{"key":"15367_CR8","first-page":"1447","volume":"29","author":"JC Allegra","year":"1979","unstructured":"Allegra, J. C. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 29, 1447\u20131454 (1979).","journal-title":"Cancer Res."},{"key":"15367_CR9","first-page":"1212","volume":"25","author":"DO Kiesewetter","year":"1984","unstructured":"Kiesewetter, D. O. et al. Preparation of four Fluorine-18 labeled estrogens and their selective uptakes in target tissues of immature rats. J. Nucl. Med. 25, 1212\u20131221 (1984).","journal-title":"J. Nucl. Med."},{"key":"15367_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2967\/jnumed.107.048546","volume":"49","author":"TK Nayak","year":"2008","unstructured":"Nayak, T. K. et al. Preclinical development of a neutral, estrogen receptor\u2013targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers. J. Nucl. Med. 49, 978\u2013986 (2008).","journal-title":"J. Nucl. Med."},{"key":"15367_CR11","doi-asserted-by":"publisher","first-page":"ii174","DOI":"10.1093\/annonc\/mdi704","volume":"16","author":"D Bafaloukos","year":"2005","unstructured":"Bafaloukos, D. et al. Neo-adjuvant therapy in breast cancer. Ann. Oncol. 16, ii174\u2013ii181 (2005).","journal-title":"Ann. Oncol."},{"key":"15367_CR12","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","volume":"365","author":"U Veronesi","year":"2005","unstructured":"Veronesi, U. et al. Breast cancer. Lancet 365, 1727\u20131741 (2005).","journal-title":"Lancet"},{"key":"15367_CR13","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/S1470-2045(13)70292-4","volume":"14","author":"M van Kruchten","year":"2013","unstructured":"van Kruchten, M. et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 14, e465\u2013e475 (2013).","journal-title":"Lancet Oncol."},{"key":"15367_CR14","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3390\/cancers16152639","volume":"16","author":"A Friedel","year":"2024","unstructured":"Friedel, A., Prante, O. & Maschauer, S. Radiosynthesis and preclinical evaluation of 18F-Labeled estradiol derivatives with different lipophilicity for PET imaging of breast cancer. Cancers 16, 2639 (2024).","journal-title":"Cancers"},{"key":"15367_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.nucmedbio.2018.01.003","volume":"59","author":"D Xu","year":"2018","unstructured":"Xu, D. et al. 18F-labeled estradiol derivative for targeting estrogen receptor-expressing breast cancer. Nucl. Med. Biol. 59, 48\u201355 (2018).","journal-title":"Nucl. Med. Biol."},{"key":"15367_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1021\/acs.bioconjchem.6b00024","volume":"27","author":"K Chauhan","year":"2016","unstructured":"Chauhan, K. et al. Bivalent approach for homodimeric estradiol based ligand: synthesis and evaluation for targeted theranosis of ER(+) breast carcinomas. Bioconjug. Chem. 27, 961\u2013972 (2016).","journal-title":"Bioconjug. Chem."},{"key":"15367_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nucmedbio.2015.09.006","volume":"43","author":"X Xia","year":"2016","unstructured":"Xia, X. et al. 99mTc-labeled estradiol as an estrogen receptor probe: Preparation and preclinical evaluation. Nucl. Med. Biol. 43, 89\u201396 (2016).","journal-title":"Nucl. Med. Biol."},{"key":"15367_CR18","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/cbdd.13754","volume":"96","author":"D Xu","year":"2020","unstructured":"Xu, D. et al. Radioiodinated estradiol dimer for estrogen receptor targeted breast cancer imaging. Chem. Biol. Drug Des. 96, 1332\u20131340 (2020).","journal-title":"Chem. Biol. Drug Des."},{"key":"15367_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nucmedbio.2020.02.007","volume":"92","author":"JA Katzenellenbogen","year":"2021","unstructured":"Katzenellenbogen, J. A. The quest for improving the management of breast cancer by functional imaging: the discovery and development of 16\u03b1-[18F]fluoroestradiol (FES), a PET Radiotracer for the estrogen receptor, a historical review. Nucl. Med. Biol. 92, 24\u201337 (2021).","journal-title":"Nucl. Med. Biol."},{"key":"15367_CR20","first-page":"1573","volume":"17","author":"JA Katzenellenbogen","year":"1997","unstructured":"Katzenellenbogen, J. A., Welch, M. J. & Dehdashti, F. The development ofestrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 17, 1573\u20131576 (1997).","journal-title":"Anticancer Res."},{"key":"15367_CR21","unstructured":"Fluoroestradiol, F. 18 \u2013 a molecular marker becomes commercially available for PET imaging in metastatic breast cancer. Mol. Imaging Siemens. https:\/\/www.siemens-healthineers.com."},{"key":"15367_CR22","unstructured":"CERIANNA\u2122 (fluoroestradiol F-18) Injection, for intravenous use Initial U.S. Approval: 2020. Reference ID: 4610145-Accessdata.fda.gov."},{"key":"15367_CR23","doi-asserted-by":"publisher","first-page":"8108","DOI":"10.1021\/jo990641g","volume":"64","author":"MB Skaddan","year":"1999","unstructured":"Skaddan, M. B., Wust, F. R. & Katzenellenbogen, J. A. Synthesis and binding affinities of novel Re-containing 7\u03b1-substituted estradiol complexes: models for breast cancer imaging agents. J. Org. Chem. 64, 8108\u20138121 (1999).","journal-title":"J. Org. Chem."},{"key":"15367_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/cge.13900","volume":"99","author":"A Szymiczek","year":"2021","unstructured":"Szymiczek, A., Lone, A. & Akbari, M. R. Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. Clin. Genet. 99, 613\u2013637 (2021).","journal-title":"Clin. Genet."},{"key":"15367_CR25","doi-asserted-by":"publisher","first-page":"1225951","DOI":"10.3389\/fphar.2023.1225951","volume":"14","author":"J Yao","year":"2023","unstructured":"Yao, J. et al. Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future. Front. Pharmacol. 14, 1225951 (2023).","journal-title":"Front. Pharmacol."},{"key":"15367_CR26","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1399-3011.2004.00160.x","volume":"63","author":"SM Okarvi","year":"2004","unstructured":"Okarvi, S. M. Synthesis: Radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent. J. Pept. Res. 63, 460\u2013468 (2004).","journal-title":"J. Pept. Res."},{"key":"15367_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-019-0539-0","volume":"9","author":"SM Okarvi","year":"2019","unstructured":"Okarvi, S. M. & Al-Jammaz, I. A. Convenient and efficient total solid-phase synthesis of DOTA-functionalized tumor-targeting peptides for PET imaging of cancer. EJNMMI Res. 9, 88 (2019).","journal-title":"EJNMMI Res."},{"key":"15367_CR28","first-page":"1650","volume":"43","author":"WA Breeman","year":"2002","unstructured":"Breeman, W. A. et al. Preclinical comparison of 111In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 43, 1650\u20131656 (2002).","journal-title":"J. Nucl. Med."},{"key":"15367_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41181-022-00171-2","volume":"23","author":"N AlHokbany","year":"2022","unstructured":"AlHokbany, N. et al. Development of new copper-64 labeled rhodamine: a potential PET myocardial perfusion imaging agent. EJNMMI Radiopharm Chem. 23, 19 (2022).","journal-title":"EJNMMI Radiopharm Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15367-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15367-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15367-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:42:35Z","timestamp":1757468555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15367-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15367"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15367-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,17]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30143"}}